证券代码：870656 证券简称：海昇药业 公告编号：2024-093 浙江海昇药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、基本情况 浙江海昇药业股份有限公司(以下简称"公司")近期获得由国家 药品监督管理局核准签发的《化学原料药上市申请批准通知书》。具 体情况如下： 生产企业：浙江海昇药业股份有限公司 地址：浙江省衢州市高新技术产业园区华阳路 36 号 通知书有效期：至 2029 年 9 月 29 日 二、其他相关信息 化学原料药名称：苯溴马隆 英文名/拉丁名：Benzbromarone 通知书编号：2024YS01019 登记号：Y20230000400 化学原料药注册标准编号：YBY71512024 包装规格：25Kg/袋*1 袋/桶 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》，经审查，本品 符合原料药审批的有关规定，批准生产本品。质量标准、包装标签及 生产工艺照所附执行。 四、备查文件 1 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-092 浙江海昇药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长行使相关 投资决策权并签署相关文件，财务负责人负责具体组织实施及办理相关事宜。 具体内容详见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关 于使用部分闲置募集资金进行现金管理的公告》（公告编号：20 ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-091 浙江海昇药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 公司于 2024 年 5 月 16 日召开第三届董事会第十六次会议、第三届监事会 第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通 过了《关于使用闲置自有资金进行现金管理的议案》，基于公司经营稳定，财务 状况稳健，有较充裕的资金及有效的风险控制制度，在确保公司正常经营活动 资金需求的前提下，公司拟使用部分闲置自有资金进行管理，以提高资金使用 效率和收益，为公司股东谋取更好的回报。公司拟进行的现金管理的金额不超 过人民币 1 亿元（含本数），资金来源为公司闲置自有资金。在上述额度内，资 金可以循环滚动使用，委托理财取得的收益可进行再投资，再投资的金额不包 含在上述额度以内。具体内容详见公司在北京证券交易所信息披露平台 （ww ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-10- | | | | | 广发证券股份有限公 | 华泰证券股份有限公 | | 08 | 830799 | 艾融软件 | 18.48 | 800000 | 司上海控江路营业部 | 司郑州经三路证券营 | | | | | | | | 业部 | | | | | | | 中泰证券股份有限公 | 东吴证券股份有限公 | | 2024-10- | 834261 | 一诺威 | 6.16 | 118000 | 司淄博中润大道证券 | 司济南明湖东路二部 | | 08 | | | | | 营业部 | 营业部 | | | | | | | 华鑫证券有限责任公 | 开源证券股份有限公 | | 2024-10- | 870656 | 海昇药业 | 15.3 | 300000 | 司上海新松江路营业 | 司上海永泰路证券营 | | 08 | | | | | 部 | 业部 | | 2024-10- | | | | | 广发证券股份有限公 ...

| | 2024-10-08 公告日期 无 | 异常期间 | | | | | --- | --- | --- | --- | --- | --- | | | 海昇药业(870656) 连续竞价 | 成交数量 （股） | 7248455 | 成交金额（万 元） | 13359.37 | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 渤海证券股份有限公司天津郑州道证券营业部 | | | 7195671.63 | 7956 | | 买2 | 华泰证券股份有限公司天津华昌道证券营业部 | | | 4961184.4 | 18564.03 | | 买3 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | | | 4832492.9 | 1208707.92 | | 买4 | 东方财富证券股份有限公司拉萨金融城南环路证券营业部 | | | 3267277.54 | 67968.11 | | 买5 | 招商证券股份有限公司深圳海天一路证券营业部 | | | 2696933.14 | 0 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-10- | 837592 | 华信永道 | 19184692.0 | 70247.5 | 异常期间涨跌幅偏离值累计 | | 08 | | | | | 达到49.40% | | 2024-10- | 430090 | 同辉信息 | 81994126.0 | 38881.63 | 异常期间涨跌幅偏离值累计 | | 08 | | | | | 达到49.40% | | 2024-10- | 830799 | 艾融软件 | 56582227.0 | 92545.85 | 异常期间涨跌幅偏离值累计 | | 08 | | | | | 达到45.73% | | 2024-10- | 872808 | 曙光数创 | 22596125.0 | 115347.21 | 异常期间涨跌幅偏离值累计 | | 08 | | | | | 达到45.66% | | 2024-10- | 833523 | 德瑞锂电 | 11452433.0 | 22311.06 | ...

三、本次股票解除限售后的股本情况 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 本次股票解除限售数量总额为 4,000,000 股，占公司总股本 5.00%，可交易 时间为 2024 年 10 月 8 日。 | 二、本次股票解除限售的明细情况及原因 | | --- | 单位：股 | | | 是否为控 | 董事、监 | | | | 尚未 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 股股东、 | 事、高级 | 本次解 | 本次解除 | 本次解除 | 解除 | | 序 | 股东姓名或名称 | 实际控制 | 管理人 | 限售原 | 限售登记 | 限售股数 | 限售 | | 号 | | 人或其一 | 员任职 | 因 | 股票数量 | 占公司总 | 的股 | | | | | | | | 股本比例 | 票数 | | | 衢州市国资信安 | 致行动人 | 情况 | | | | 量 | | | 资本管理有限公 | | | | | | | | ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-089 浙江海昇药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 | 受托方 | | 产品类 | 产品名称 | 产品金 额（万 | 预计年化收 | 产品期 | 收益 | 投资 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 型 | | | 益率（%） | 限 | 类型 | 方向 | 来源 | | | | | | 元） | | | | | | | 杭 | 州 | 银行理 | 杭州银行 | 2,500 | 1.25~2.65 | 25 天 | 保本 | 结构 | 自有 | | 银 | 行 | 财产品 | "添利宝" | | | | 浮动 | 性存 | 资金 | | 股 | 份 | | 结构性存款 | | | | 收益 | 款 | | | 有 限 | | | ...

证券代码：870656 证券简称：海昇药业 公告编号：2024-088 浙江海昇药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东大会，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长行使相关 投资决策权并签署相关文件，财务负责人负责具体组织实施及办理相关事宜。 具体内容详见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关 于使用部分闲置募集资金进行现金管理的公告》（公告编号：2024-069）。 （二）本次委 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥70,947,999.30, a decrease of 44.01% compared to ¥126,708,771.81 in the same period last year[16]. - The net profit attributable to shareholders was ¥23,449,034.92, down 56.55% from ¥53,965,557.28 year-on-year[16]. - The gross profit margin for the first half of 2024 was 44.19%, down from 55.25% in the same period last year[16]. - The basic earnings per share decreased by 65.56% to ¥0.31 from ¥0.90 year-on-year[16]. - The net cash flow from operating activities was 18,507,184.68 yuan, reflecting a decline of 51.91% compared to the previous year[29]. - The total operating income for the period was ¥26,968,545.47, down 57.0% from ¥62,835,042.09 in the previous period[199]. - The company reported a net profit of ¥23,449,034.92, a decrease of 56.5% compared to ¥53,965,557.28 from the previous year[200]. Assets and Liabilities - The total assets increased by 115.57% to ¥662,601,544.39 from ¥307,375,267.23 at the end of the previous year[17]. - The total liabilities rose by 64.15% to ¥37,724,623.61 compared to ¥22,982,422.60 at the end of the previous year[17]. - The net asset attributable to shareholders increased by 119.72% to ¥624,876,920.78 from ¥284,392,844.63 year-on-year[17]. - Cash and cash equivalents increased by 210.46% to ¥314,755,697.46, primarily due to funds raised from a public stock offering[34]. - The total assets and liabilities combined reached ¥662,601,544.39, up from ¥307,375,267.23, marking a growth of 115.5%[99]. Shareholder and Dividend Information - The company completed a cash distribution of ¥5.00 per share to shareholders based on a total of 80,000,000 shares on June 11, 2024[3]. - The company plans to distribute a cash dividend of ¥5.00 per share based on the current share capital of 80,000,000 shares[196]. - The actual controllers committed to extend the lock-up period of their shares by 12 months until August 2, 2026[61]. - The actual controllers promised to enhance the cash dividend policy to improve investor returns[61]. Market and Competitive Position - The global veterinary drug market size was approximately $44.59 billion in 2022, expected to reach $83.76 billion by 2030, with a CAGR of 8.2%[31]. - The domestic veterinary drug market is projected to grow from 68.62 billion yuan in 2021 to 139.57 billion yuan by 2027, with a CAGR of 12.56%[32]. - The company has strengthened its domestic and international product registrations to lay the foundation for future revenue growth[29]. - The company is currently benefiting from tax incentives related to high-tech enterprises, which could be impacted if conditions change[52]. Research and Development - The company established a new R&D building in May 2024 to enhance its research capabilities[2]. - The company is increasing R&D investment to mitigate risks from market competition and product concentration, focusing on developing new products and optimizing existing processes[52]. - Research and development expenses for the first half of 2024 were CNY 4,047,841.27, a decrease of 18.3% compared to CNY 4,953,819.84 in the first half of 2023[100]. Environmental and Safety Compliance - The company adheres to the "three-level standard" for wastewater discharge, ensuring compliance with environmental regulations[43]. - The company’s waste gas emissions are treated according to national standards, with measures in place for VOCs control and acid-base treatment[47]. - The company has implemented a waste management strategy focusing on resource recovery, reduction, and harmlessness, with hazardous waste being disposed of by qualified third-party institutions[48]. - The company is committed to improving safety and environmental management to prevent potential accidents[53]. Governance and Management - The board of directors consists of 6 members, while the supervisory board has 3 members, indicating a stable governance structure[91]. - The company has appointed new management personnel, including Mr. Shu Lin and Mr. Yang Chun, enhancing its leadership team[95]. - There were changes in independent directors, with Li Liangchen resigning for personal reasons and Shu Lin being appointed as a new independent director[94]. Related Party Transactions - The company has a debt relationship with related parties, with accounts payable to Ye Shan Hai and Ye Jin Zhi amounting to CNY 9,798,100.00 and CNY 9,900,000.00 respectively[59]. - The company will ensure that any related party transactions are conducted on an equal and voluntary basis, adhering to fair and reasonable pricing principles[75]. Stock Price Stabilization Measures - The company has committed to stabilizing its stock price for three years following its public offering on the Beijing Stock Exchange, with specific measures to be implemented if stock prices fall below the issuance price for 10 consecutive trading days within the first month[66]. - The company’s stock price stabilization plan is designed to ensure compliance with the listing conditions of the Beijing Stock Exchange[67]. - The company will not allow any share transfers by directors and senior management during a lock-up period of 12 months post-IPO, with a maximum of 25% of their holdings allowed for transfer annually thereafter[65]. Financial Reporting and Compliance - The financial statements are prepared based on the going concern assumption, indicating no significant doubts about the company's ability to continue operations for the next 12 months[115]. - The company adheres to the accounting standards set by the Ministry of Finance and reflects its financial status accurately as of June 30, 2024[116]. - The company guarantees that the prospectus and other issuance documents do not contain false records or misleading statements, and assumes legal responsibility for their authenticity, accuracy, and completeness[71].